NewAmsterdam Pharma reports $729M year-end cash

NewAmsterdam Pharma Company N.V. furnished an update on its financial position and recent progress.

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. furnished an update on its financial position and recent progress. The company reported that unaudited cash, cash equivalents and marketable securities totaled approximately $729 million as of December 31, 2025, providing a view of its liquidity at year-end. This figure was shared in a press release that also highlighted the company’s 2025 achievements and outlined its strategic priorities for 2026.

The press release is included as an exhibit to the report and is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What key financial figure did NewAmsterdam Pharma (NAMS) disclose in this 8-K?

NewAmsterdam Pharma reported unaudited cash, cash equivalents and marketable securities of approximately $729 million as of December 31, 2025.

As of what date is NewAmsterdam Pharma’s $729 million cash balance measured?

The approximately $729 million in cash, cash equivalents and marketable securities is stated as of December 31, 2025.

What else did NewAmsterdam Pharma highlight alongside the cash balance update?

The company issued a press release highlighting its 2025 achievements and outlining its 2026 strategic priorities in addition to disclosing the cash balance.

How is the NewAmsterdam Pharma press release treated for securities law purposes?

The press release, along with the information in Items 2.02 and 7.01, is being “furnished” and not deemed “filed” under the Exchange Act or Securities Act, unless specifically incorporated by reference elsewhere.

Where can investors find the detailed NewAmsterdam Pharma 2025 achievements and 2026 priorities?

Those details are contained in the company’s press release furnished as Exhibit 99.1 to the report.

Who signed the NewAmsterdam Pharma 8-K update on behalf of the company?

The report was signed by Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma Company N.V.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 08:00 AM Learn about SEC filing dates

false000193625800-000000000019362582026-01-092026-01-090001936258us-gaap:WarrantMember2026-01-092026-01-090001936258us-gaap:CommonStockMember2026-01-092026-01-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

The Netherlands			001-41562	N/A
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Goomieer 2-35
Naarden
The Netherlands				1411 DC
(Address of Principal Executive Offices)				(Zip Code)
			+31 (0) 35 206 2971
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value €0.12 per share		NAMS		The Nasdaq Stock Market LLC
Warrants to purchase ordinary shares		NAMSW		The Nasdaq Stock Market LLC

☐	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 9, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release highlighting its 2025 achievements and outlining 2026 strategic priorities. In this press release, the Company announced that its unaudited cash, cash equivalents and marketable securities balance as of December 31, 2025 was approximately $729 million.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in Item 2.02 and Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 9, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NewAmsterdam Pharma Company N.V.
Date:	January 9, 2026	By:	/s/ Ian Somaiya
		Name:	Ian Somaiya
		Title:	Chief Financial Officer